Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist also used for diabetes management, is associated with a significant resolution of signs of NASH [23]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.